Emerging Scientific Platforms

As the understanding of oncology progresses, it has become clear that the fight against cancer requires innovation from many angles. With a multifaceted approach to research and development, Genentech is investigating a broad range of antitumor modalities, including individualized neoantigen specific therapy, innovative bispecific antibodies, and novel antibody drug conjugates.

In the continued pursuit of truly personalized medicine, Genentech aims to improve specificity across all development platforms, to further identify the right approach for the right patient, and to transform the way cancer is treated in areas of unmet clinical need.


  1. Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35. pii: e00225. PMID: 26182432
  2. Polson AG, Yu S-F, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616-623. PMID: 17374736
  3. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222-226. PMID: 28678784
  4. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist. 2007;12:1084-1095. PMID: 17914078
  5. Hanahan D, Weinberg D. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. PMID: 21376230
  6. Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381-405. PMID: 28431241
  7. Bacac M, Klein C, Umana P. CEA TCB: a novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5:e1203498. PMID: 27622073
  8. Bacac M, Fauti T, Sam J, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286-3297. PMID: 26861458